To the editor: Visitor contributors Jennifer Weiss-Wolf and Suzanne Gilberg are 100% appropriate and contact upon an issue not simply severely hurting girls, however the whole inhabitants (“Focus on the real causes of the shortage in hormone treatments,” April 20). Trendy economics has confirmed that any oligopsony might be simply as market-manipulative as important monopolies. With 85% of the drugs managed by just four buyers, it’s no shock that we get squeezed with shortages and shoppers truly pay extra.
America sees this with pharmacy profit managers (PBMs) and hospital group buying organizations, in addition to in a lot of our nation’s hospital chains and medical health insurance. Rural America and inside cities are hit particularly laborious. The hormone patch dilemma is equivalent to how physicians and bodily and occupational therapists have had their reimbursements squeezed as their value of doing enterprise goes up, and sufferers are compelled into slim networks and restricted hospital selection.
The complete PBM trade is all about kickbacks and market manipulation. The extra rent-takers, the extra compelled manipulation of shoppers. The much less transparency there may be, the much less free any market might be. Oligopsony is the antithesis of a free market and straight results in elevated shopper costs.
The secure harbor permitting kickbacks and market manipulation for PBMs must be rescinded, slim networks outlawed and hospital grasp expenses obtainable for each invoice over $20.
Howard C. Mandel, Los Angeles
This author is president emeritus of the Los Angeles Metropolis Well being Fee.
..
To the editor: PBMs actively encourage using generic medication as a result of they’re secure, efficient and dramatically extra inexpensive than their model counterparts, which saves everybody cash. That is true within the case of hormone therapies, opposite to the assertions of a latest op-ed.
When issues come up concerning the availability of low-cost medication, the primary questions ought to be about provide. Why are drug producers making fewer generics within the first place? The estradiol patch is only one instance of an endemic scarcity downside for generic medication. Over time, systemic provide chain points have mixed with model drug producers’ utilizing practices to dam competitors and shrink the pool of inexpensive choices sufferers depend on.
PBMs at all times welcome these lower-cost options as a result of extra generics imply extra competitors, which ends up in decrease costs and higher entry for sufferers.
The best way to generate extra inexpensive choices is stopping practices by model drugmakers that block competitors, quite than blaming PBMs — the one a part of the system working to safe financial savings and broaden entry each day.
Amanda Frost, Washington
This author is vice chairman of analysis for the Pharmaceutical Care Administration Assn.
..
To the editor: Thanks for the eye-opening op-ed on the true causes of the scarcity in hormone therapies.
I’ve been denied refills of the estradiol patch for months now, regardless of utilizing it for years. My pharmacy had not urged options, so I used to be again within the hell of sizzling flashes. Apparently, my twice-weekly estradiol patch just isn’t obtainable as a result of it has a negligible revenue margin.
I used to be saddened to learn that the identical company that sells me my insurance coverage plan additionally decides which medication get coated at what value and whether or not my pharmacy can inventory them. I additionally discover it legal that many ladies going via the difficulties of menopause can not entry medication that can make their lives a lot simpler.
Lorraine Montgomery, Pasadena
..
To the editor: The op-ed on the scarcity of estradiol patches was of nice curiosity to me, a person with prostate most cancers. A latest research printed within the New England Journal of Medicine discovered that the patches have been as efficient as conventional androgen deprivation remedy however supply a number of benefits akin to decrease value, ease of software and retention of bone density.
I used to be interested in the price, as this can be a generic drug that has been in use for many years. The costs I discovered on GoodRx have been surprising, with some greater than a number of hundred {dollars} a month.
Clearly the system just isn’t working for the buyer. Competitors is meant to decrease costs, however the comfort of so many healthcare firms has allowed them to artificially inflate costs. Sadly, this comes at a time when the federal authorities has considerably decreased its position in shopper safety.
Alan Coles, Lengthy Seaside
